Article info

PDF
Original article
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Authors

  1. Correspondence to Catherine L Shuler; shuler_catherine_l{at}lilly.com
View Full Text

Citation

Coates LC, Kishimoto M, Gottlieb A, et al
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

Publication history

  • Received 25 August 2017
  • Revision received 16 October 2017
  • Accepted 5 November 2017
  • Published online 22 December 2017.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.